# Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

> **NCT00323063** · PHASE2 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 49 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00323063
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05-01
- **Primary completion:** 2011-04-15
- **Final completion:** 2016-06-20
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323063, "Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00323063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*